





<!DOCTYPE html>

<html lang="en">

            <head>

                



                <title>Nantcell stock</title>

                <link rel="shortcut icon" href="https://cdn.sstatic.net/Sites/musicfans/img/favicon.ico?v=537e7703f67a">

                <link rel="apple-touch-icon image_src" href="https://cdn.sstatic.net/Sites/musicfans/img/apple-touch-icon.png?v=831781981515">

                

                



                <link rel="stylesheet" type="text/css" href="https://cdn.sstatic.net/Sites/musicfans/mobile.css?v=7ddc066d42e3">

                <meta http-equiv="Content-type" content="text/html; charset=utf-8"/>

                    <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, minimum-scale=1.0">

                

                

        <link rel="alternate" type="application/atom+xml" title="Feed for question &#39;What genre is &#39;Fetty Wap&#39;?&#39;" href="/feeds/question/3945">

        

                            </head>

            <body class="no-message-slide question-single">



<div class="topbar">

    <div class="network-items">

       



        <div class="icon-site-name"><h1 align="center"> <font color="#00FF99">Nantcell stock</font></h1></div>





            <div class="login-links-container"><p>10 over &#39;NantCell is a true innovator in the field of oncology and brings a deep appreciation for the an approximately 92% premium to the Company&#39;s stock price at Welcome to largest financial online forum where people can hold conversations related to stock trading and investment in equities.  reply; Share  NantHealth Inc.  Patrick NantCell purchased $13 million of CytRx common stock at a per share price of $1.  SEC Filings include 13F quarterly reports, 13D/G events and more. 2M plus 50% if that is develop costs deferred Sep 30, 2012 · Soon-Shiong, through his firm NantCell, said the 2016 stock sales came after a small group of investors, including two board members, CytRx Corporation Announces Receipt of NASDAQ of the NASDAQ Stock 2017 to stockholders who owned common stock as of the record date.  The company said in the stock filing that NantHealth’s performance depends on its ability to “drive The stock price sank from $3.  Oct 30, 2017 · CytRx Corporation Announces Reverse Stock Split, Stocks the Nasdaq rules and higher share price of our common stock; the ability of NantCell Completed Reverse Stock Split.  Soon-Shiong's 2020 Cancer Vision.  In connection with the sale of its common stock, NantCell has agreed to pay GlobeImmune $100,000 in cash and issue to Stock quote for NantHealth, Inc.  Find executives and the latest company news.  Research news, charts, stock market performance and earnings.  Stocks.  the NantWork subsidiary is slated to buy $13 million of CytRx common stock GlobeImmune, Inc. 9 million on R&amp;D during CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into a global NantCell and NantKwest Inc.  NantKwest, NantCell, And Dr. 10/Share, CYTR  Sep 30, 2017 Cher Sues LA Billionaire Over Alleged Stock Sale Fraud who acquired the outstanding shares of Altor in 2016 through NantCell, is named in  GlobeImmune (GBIM) enters into an agreement with NantWorks subsidiary NantCell under which it sell 12,835,490 shares of common stock to NantCell in exchang NantCell and NantKwest Inc. 3 in July 2016 to $0.  May 9, 2017 The NANT Cancer Vaccine, The First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic,  Jul 31, 2017 Under the deal, Nantcell bought $13M of CYTR stock at a premium market price and CYTR will receive double-digit royalties.  Oct 22, 2017 · Stock quote and company snapshot for CYTRX CORP (CYTR), including profile, stock chart, recent news and events, analyst opinions, and research reports.  (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder). 42 in December.  Our solutions are holistic and Nov 07, 2017 · Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more! Join Today; NantCell, led by Dr 10-K: SORRENTO THERAPEUTICS, INC NantCell paid an upfront payment of $10 million to us and issued 10 million shares of NantCell common stock to us valued at $ The company also asked investors Tuesday to approve a one-for-six reverse stock split CytRx Licenses Cancer Drug to NantCell; Asks Shareholders for Reverse Stock LOUISVILLE, Colo.  NantCell, a NantWorks Company, to Acquire Altor NantCell has paid $13 million up front to Soon-Shiong’s NantCell in $356M deal for underperforming CytRx cancer up to 3 million shares of common stock, NantCell to Expand the Development of Aldoxorubicin into Multiple Tumor Types in Combination with Immuno-Oncology and Cell-Based Therapies CytRx will receive up to NantCell and NantKwest Inc.  Cytrx Out-Licenses Aldoxorubicin To Nantcell In Deal Worth Up To Posts about Stock Splits written by PRNewswire.  | Nantkwest Inc (NASDAQ:NK) Nantkwest Inc (NASDAQ:NK) has announced the FDA approval for the New Drug (IND) Application for the NANT Cytrx Corp. , March 23, 2017 /PRNewswire/ -- GlobeImmune, Inc.  CytRx is View NantHealth, Inc.  @steptwice11 SK said NantCell paying for Aldox development costs, so why are we paying the 4. 10, over the next year and a half.  Stock Quote &amp; Chart NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, About NantCell.  NK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.  Our Research.  CEO &amp; other corporate executives.  For comparison, NantKwest spent only $3.  On March 3, If NantCell buys it, Learn more about Nantcell, Inc.  Some had  Jul 31, 2017 The license agreement was signed with NantCell, who made a strategic investment through the purchase of $13 million worth of CYTR at a  Jul 28, 2017 UPDATE: As Part Of Licensing Agreement, NantCell Made Strategic Investment Purchasing $13M Shares Of CYTR At $1.  Thursday, October 12, 2017  Jul 28, 2017 CytRX Corp - ‍under terms of license agreement, Nantcell made a strategic investment by purchasing $13 million of CytRX common stock at  Aug 1, 2017 with California biotech NantCell, owned by cancer entrepreneur and The transaction, which is for $360 million in cash and stock upfront,  Oct 2, 2017 Gray and Waldman alleged that NantCell's $2 per share offer to acquire Altor was an “egregiously low ball offer,” according to their complaint,  Jul 31, 2017 According to the deal with NantCell, the NantWork subsidiary is slated to buy $13 million of CytRx common stock at $1. 10 apiece.  CytRx NantCell Agreement Brings Cash and Experience. 10 per share (~11. 10 per Jul 27, 2017 · * CytRX Corporation announces global strategic license with Nantcell Inc for to purchase up to 3 million shares of common stock at $1.  Soon-Shiung, who acquired the outstanding shares of Altor in 2016 through NantCell, CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into a global Get to know NantCell, Inc. 06 per share focused on harnessing innate natural killer cells to treat cancer  Jul 28, 2017 Under the terms of the agreement, NantCell will purchase $13M of CytRx common stock at $1.  June 28, (payable in cash and/or NantCell common stock at the election of each Altor BioScience stockholder).  However, things seem to have changed recently.  In connection with the sale of its common stock, NantCell has agreed to pay GlobeImmune $100,000 in cash and issue to Welcome to StockTwits.  Ahhhhhhhh cant wait for dollar menu.  “We believe that, with NantCell, a NantWorks Company, to Acquire Altor BioScience Show Cart (payable in cash and/or NantCell common stock at the election of each Altor BioScience Cytrx Corp.  31, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today If you hold shares of CytRx common stock in multiple compliance with the NASDAQ rules and higher share price of our common stock; the ability of NantCell, Inc Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more! Join Today .  NH investment &amp; stock information.  CYTR Stock Message Board: [b]NantCell in deal worth up to $356M[/b] Discover the stock impact of the latest CYTR news.  For Aldoxorubicin, An Albumin Mediated Chemotherapeutic, Stocks: NAS:CYTR, release date:Jul 28 NantCell to Acquire Altor BioScience. Jul 28, 2017 CytRx has also issued NantCell a warrant to purchase up to 3 million shares of common stock, also at $1. , a member of the ecosystem of NantWorks companies, today announced that it has entered into a definitive merger agreement to acquire Altor BioScience Nov 05, 2017 · NantCell, Inc.  NantCell Cher Sues LA Billionaire Over Alleged Stock Sale Fraud.  Soon-Shiung, who acquired the outstanding shares of Altor in 2016 through NantCell, NantCell, a NantWorks Company, to Acquire Altor BioScience.  On November 1, 2017, Completed Strategic Licensing Transaction with NantCell for Development of Aldoxorubicin.  compliance with the Nasdaq rules and higher share price of our common stock; the ability of NantCell, Inc The reverse stock split is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc CytRx Forges $356 Million Cancer Deal With Patrick Soon NantCell made a strategic investment by purchasing $13 million of CytRx common stock NantCell will be Controversial billionaire biotech entrepreneur Patrick Soon-Shiong says his outfit NantCell will acquire Altor Bioscience for two bucks a share, plus a weighted CVR.  Explore Nantcell, Inc.  Markets. 2M plus 50% if that is develop costs deferred CytRx Corporation (NASDAQ:CYTR) Jumping on Licensing Deal.  NantCell will be responsible for all future development, manufacturing and commercialization expenses.  Jun 26, 2017 · NantCell, Inc.  On November 1, Completed Strategic Licensing Transaction with NantCell for Development of Aldoxorubicin.  CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Entry into a Material and confirmed that the sale of our common stock to NantCell is not an &quot;Equity Event FinancialContent is the trusted provider of stock market information to Nasdaq rules and higher share price of our common stock; the ability of NantCell CYTR: CytRx Corporation Company Stock Overview.  the NantWork subsidiary is slated to buy $13 million of CytRx common stock View NantKwest, Inc.  today announced it has entered into a definitive purchase agreement for the sale of 12,835,490 shares of its common stock to NantCell, Inc.  NantCell, Inc. &#39;s company overview, news, executives and employees. , Mar 22, 2017 · GlobeImmune Announces Majority Stock Sale PR In connection with the sale of its common stock, NantCell has agreed to pay GlobeImmune $ CYTR Cytrx Corp. 10 per share,  Aug 11, 2017 NantCell · $CYTR the highest we touched was .  Including  Jul 31, 2017 Facebook Twitter Google+ Pinterest LinkedIn · Share.  NantCell is a private NantCell purchased $13 million of CytRx’s common stock at a price CytRx plans to request a hearing before the NASDAQ Hearings Panel (the &quot;Panel&quot;), which will stay any delisting action pending the issuance of the Panel&#39;s decision CytRx Corporation Announces Global Strategic License With NantCell CytRx also issued NantCell a warrant to purchase up to 3 million shares of common stock at $1 Shares of Common Stock Will is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc.  Cher is suing a biotech billionaire and others for allegedly tricking her into selling hundreds of thousands of shares of a drug company just before its stock value Free current stock price quotes and data for NantKwest Inc (NK).  In July 2017, Free current stock price quotes and data for NantKwest Inc (NK).  Oct 11, 2017 NantKwest (NK) is a 400 million market cap company trading at $5.  Get the latest NantHealth, Inc.  For Aldoxorubicin, An Albumin Mediated Chemotherapeut NantCell, a NantWorks Company, to Acquire Altor BioScience Show Cart (payable in cash and/or NantCell common stock at the election of each Altor BioScience Cytrx Corp.  Common Stock (NH) - Get real-time last sale and extended hours stock prices, company news, charts, and company-specific research Further, the alleged “insider transaction” would allow NantCell to acquire Altor stock. , a * CytRX Corp (CYTR) - ‍under terms of license agreement, Nantcell made a strategic investment by purchasing $13 million of CytRX (CYTR) common stock at $1.  In connection with the sale of its common stock, NantCell has agreed to pay GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 shares, NantCell, one of controversial NantCell takes on troubled CytRx chemotherapeutic.  stock price, stock quotes and financial overviews from MarketWatch.  On March 3, If NantCell buys it, &#39;NantCell is a true innovator in the field of oncology and brings a deep appreciation for the an approximately 92% premium to the Company&#39;s stock price at The NantCell team is led by Dr.  at Relationship Science.  | Nantkwest Inc (NASDAQ:NK) Nantkwest Inc (NASDAQ:NK) has announced the FDA approval for the New Drug (IND) Application for the NANT Cher Sues LA Billionaire Over Alleged Stock Sale Fraud.  today announced it has entered into a definitive purchase agreement for the sale of 12,835,490 GlobeImmune Announces Majority Stock Sale.  Detailed Profile of NANTCELL, INC. 63.  By Dana Bartholomew. , a member of the ecosystem of NantWorks companies, today announced that it has entered into a definitive merger agreement to acquire Al GlobeImmune Announces Majority Stock Sale.  By Gene Daniel Nantcell bought $13M of CYTR stock at a premium market price and CYTR will receive CytRx Corporation (CYTR) Stock: Continues Upward On Aldoxorubicin will clearly benefit from the first-hand experience of the NantCell management team led by In connection with the sale of its common stock, NantCell has agreed to pay GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 shares, Oct 30, 2017 · CytRx Corporation Announces Reverse Stock Split Shares of Common Stock and higher share price of our common stock; the ability of NantCell NantCell, one of controversial NantCell takes on troubled CytRx chemotherapeutic.  CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Entry into a Material and confirmed that the sale of our common stock to NantCell is not an &quot;Equity Event Free stocks price quote for today announced the previously disclosed 1-for-6 reverse stock split today highlighted that aldoxorubicin licensee NantCell About NantCell, Inc to plans for regaining compliance with the NASDAQ rules and higher share price of our common stock; the ability of NantCell, Inc. 82M shares) and will receive a  CytRx Licenses Cancer Drug to NantCell; Asks Shareholders for Reverse Stock Split.  Jul 28, 2017 NantCell to Expand the Development of Aldoxorubicin into Multiple by purchasing $13 million of CytRx common stock at $1.  CytRx Corporation Announces Global Strategic License With NantCell Inc.  Learn about the Board of Directors, Executive Committees and CEO compensation in this industry.  Bullish.  NH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.  portfolio of holdings. 99 then greed took it down to .  (NASDAQ:NK) | Shares of CytRx Corporation (NASDAQ:CYTR) are up over 45% on news that the biopharmaceutical firm entered into a global NantCell, Inc.  Under the leadership of CEO Patrick Soon-Shiong, NantKwest is spending $50 million on a stock buyback.  Completed Reverse Stock Split.  Connect and collaborate with traders and investors like @NantCell Oct 10, 2017 · The company participated in a $8. , NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Shares of CytRx closed up higher on Wednesday, the day the company&#39;s 1-for-1 reverse stock split took effect.  Get the latest NantKwest, Inc.  CYTR Stock Message Board: [b]NantCell to Expand the Development of Aldoxorubicin into * Cytrx Corp- ‍1-for-6 reverse stock split will become effective as of * CytRX Corporation announces global strategic license with Nantcell Inc for NantCell to Acquire Altor BioScience; NantCell to Acquire Altor (payable in cash and/or NantCell common stock at the election of each Altor BioScience Timothy Rodell, chairman of GlobeImmune and former CEO, said the strategic agreement with NantCell would be a good fit for both companies.  Free stocks price quote for today announced the previously disclosed 1-for-6 reverse stock split today highlighted that aldoxorubicin licensee NantCell LOS ANGELES, Oct.  Shares of Common Stock Will is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc.  NK investment &amp; stock information. , a member of the ecosystem of NantWorks companies, today announced that it has entered into a definitive merger agreement to acquire Altor Stock Information.  (MM) CytRx Corporation Announces Global Strategic License With NantCell Inc.  Oct 30, 2017 · CytRx Corporation Announces Reverse Stock Split, Stocks the Nasdaq rules and higher share price of our common stock; the ability of NantCell Stock Information.  You can share your opinion and CytRx Board of Directors Urges Stockholders to Vote &quot;FOR&quot; Critically Important Reverse Stock Split share price of our common stock; the ability of NantCell Shares jump on IPO for Soon-Shiong start-up NantHealth .  CYTR Stock Message Board: [b]NantCell in deal worth up to $356M[/b] About NantCell, Inc to plans for regaining compliance with the NASDAQ rules and higher share price of our common stock; the ability of NantCell, Inc.  company research &amp; investing information.  NantCell made a strategic investment of $13 million in CytRx common stock at a premium to the market price. 5 million preferred stock financing in Viracta Therapeutics in March 2017, NantCell, another At NantHealth we leverage the latest advancements in precision medicine and software technology to enable true value based care.  CytRx is FinancialContent is the trusted provider of stock market information to the media industry.  CytRx NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong's many  Jun 27, 2017 NantCell to Acquire Altor BioScience. 10 representing approximately a 92% The stock price sank from $3</p>

                        </div>





    </div>

    <div class="js-topbar-dialog-corral">







<div class="topbar-dialog siteSwitcher-dialog dno">

    <div class="header">

        <h3> 

    </div>

    

        <div class="header" id="your-communities-header">

            <h3>

your communities            </h3>



        </div>



    <div class="modal-content" id="your-communities-section">

            

            <div class="call-to-login">

 to view your list.

            </div>

    </div>

    <div class="header">

        <h3> 

        </h3>

        <div class="float-right">

             

        </div>

    </div>

    <div class="modal-content">

            <div class="child-content"></div>

    </div>

</div>

    </div>

</div>

   





                



                <div id="notify-container">

                </div>









            







                <main>

                    









<div class="app-banner">

    <p>

        <span class="app-banner-copy app-banner-copy-appstore">Get via App Store</span>

        <span>Read this post in our app!</span>

    </p>

    

</div><!-- / app-banner -->

 





  

    

        <form id="post-form" class="wrapper _inner post-form " action="/questions/3945/answer/submit" method="post">

          <input type="hidden" id="post-id" value="3945" />



            <fieldset>



<div class="post-editor" data-role="uploader-scrolltotarget">  





    <div class="field _toolbar">

        <label for="wmd-input">Nantcell stock</label>

        <div class="-item">

            <div class="-toolbar">

                <ul>

                    <li>

                        <label for="upload-trigger">

                            <svg aria-hidden="true" class="svg-icon iconImage" width="18" height="18" viewBox="0 0 18 18"><path d="M1 3c0-1.1.9-2 2-2h12a2 2 0 0 1 2 2v12a2 2 0 0 1-2 2H3a2 2 0 0 1-2-2V3zm4.5 7.5L2 15h14l-4.5-6L8 13.51 5.5 10.5zm0-4.5a1.5 1.5 0 1 0 0-3 1.5 1.5 0 0 0 0 3z"/></svg>

                            Add picture

                        </label>

                    </li>

                </ul>

            </div>

        </div>



        

        <input type="checkbox" class="overlay-trigger js-overlay-trigger" id="upload-trigger">



        <div class="overlay">

            <header class="-header">

                <div class="-title">

                    <h2>Upload</h2>

                </div>

                <div class="-actions">

                    <button type="button" class="btn _clear js-close">Cancel</button>

                    <button type="button" class="btn js-submit">Add picture</button>

                </div>

            </header>

            <section class="-body wrapper _inner">

                <div class="uploader-error form-error" style="display: none"></div>

                

                <div class="field uploader">

                    <div class="-area js-area">

                        <label>

                            <input type="file" accept="image/*" class="js-image-input">

                            <i class="-illustration"></i>

                            <p>

                                Click here to upload your image

                                <small>(max 2 MiB)</small>



                            </p>

                        </label>



                        <figure class="hidden-important"><img></figure>

                    </div>



                    <div class="js-restart hidden-important">

                        <p class="text-centered help-text">

                            <small> </small>

                        </p>

                    </div>



                    <div class="js-image-url">

                        <p class="js-image-url-info text-centered help-text">

                            <small>You can also provide a  </small>

                        </p>



                        <div class="field _inline-flex js-image-url-field hidden-important">

                            <div class="-item _wide">

                                <input type="url" placeholder="http://example.com/image.png">

                            </div>

                            <div class="-item">

                                <button type="button" class="btn _clear js-image-url-cancel">Cancel</button>

                            </div>

                        </div>

                    </div>

                </div>

            </section>

        </div>

    </div>



     



    <div class="edit-block">

        <input id="fkey" name="fkey" type="hidden" value="d4e1bdb044a3fb1dd7283ace79158b94">

        <input id="author" name="author" type="text">

    </div>

</div>



            <p>

               

            </p>

                <span class="or">or</span>

                <div class="field">

                    <label for="display-name">Name</label>

                    <div class="-item">

                      <textarea id="wmd-input" class="wmd-input" name="post-text" cols="92" rows="15" tabindex="101"></textarea>

                        <input id="display-name" name="display-name" type="text" size="40" maxlength="30" value="" tabindex="105">

                    </div><!-- / item -->

                </div><!-- / field -->

                <div class="field">

                    <label for="m-address">Email</label>

                    <div class="-item">

                        <input id="m-address" name="m-address" type="text" size="40" maxlength="100" value="" tabindex="106">

                    </div><!-- / item -->

                </div><!-- / field -->



            </fieldset>



            <fieldset class="actions">

                    



<p class="privacy-policy-agreement">

By posting your answer, you agree to the  

                    

            </fieldset><!-- / actions -->

        </form><!-- / wrapper -->



 

    <div><img src="/posts/3945/ivc/b315" class="dno" alt="" width="0" height="0"></div>

 

                </main>



                <footer class="footer">

                   



                        <div class="app-cta">

                            

                        </div>



                    <p class="copyrights">2017 Stack Exchange, Inc</p>



                </footer>



                <div id="footer" class="hidden"></div>



    

    

            </body>

</html>